Greendale, WI, United States of America

Everett R Tate

USPTO Granted Patents = 2 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2023-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Everett R. Tate

Introduction

Everett R. Tate is a notable inventor based in Greendale, WI (US). He has made significant contributions to the field of medical science, particularly in the development of novel antibodies for cancer treatment. With a total of 2 patents, his work has the potential to impact cancer therapies significantly.

Latest Patents

Tate's latest patents include groundbreaking inventions related to Anti-CD30 antibodies. The first patent provides novel antibodies and antigen binding fragments that bind to human CD30. It also presents single chain variable antibodies, chimeric antigen receptors, and methods for treating cancer. The second patent similarly focuses on Anti-CD30 antibodies and methods for treating CD30+ cancer, further emphasizing the importance of these innovations in cancer treatment.

Career Highlights

Throughout his career, Tate has worked with esteemed institutions such as the Medical College of Wisconsin, Inc. and the University of Virginia. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to significant advancements in medical research.

Collaborations

Some of his notable coworkers include Mary L. Faber and Robyn A. A. Oldham. Their collaborative efforts have likely played a role in the success of his innovative projects.

Conclusion

Everett R. Tate's contributions to the field of cancer treatment through his innovative patents highlight his dedication to improving medical science. His work continues to inspire future research and development in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…